New pill targets rare cancer gene in early trial
Disease control
Recruiting now
This study tests an experimental oral drug called 3HP-2827 in people with advanced solid tumors that have specific changes in the FGFR2 gene. The trial has two parts: first, finding the safest dose, then testing how well it shrinks tumors. About 130 adults with cancers that canno…
Phase: PHASE1, PHASE2 • Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC